Genomictree

Genomictree OCF Margin

The Operating Cash Flow Margin of Genomictree (228760.KQ) as of Nov 3, 2026 is -271.08 %. In the previous year, Operating Cash Flow Margin was -577.12 % — a change of -53.03% (higher).

OCF Margin

-271.08 %

YoY

-53.03%

Last updated:

Operating Cash Flow Margin of Genomictree is 2025 -271.08 % . Operating Cash Flow Margin of Genomictree was 2024 -577.12 % . It decreases by -53.03% higher compared to the previous year.

The Genomictree OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2017
-404.70 KRW
Jan 1, 2019
-3,291.77 KRW
Jan 1, 2020
-822.34 KRW
Jan 1, 2021
-148.47 KRW
Jan 1, 2022
14.35 KRW
Jan 1, 2023
-318.33 KRW
Jan 1, 2024
-577.12 KRW
Jan 1, 2025
-271.08 KRW
The Genomictree OCF Margin history
YEAROCF MarginYoY
-271.08 %-53.03%
-577.12 %+81.30%
-318.33 %-2,318.37%
14.35 %-109.67%
-148.47 %-81.95%
-822.34 %-75.02%
-3,291.77 %+713.39%
-404.70 %+231.58%
-122.05 %+83.54%
-66.50 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genomictree Stock analysis

What does Genomictree do? Genomictree, Inc. generates revenue by developing and supplying diagnostic products focused on cancer screening and prognosis. The firm conducts genomic analysis using microarrays and next generation sequencing analysis, while also performing clinical trials for its molecular diagnostic products. These offerings are designed to support medical professionals in identifying and managing various oncological conditions through advanced genetic testing methodologies. The company’s product portfolio is divided into cancer molecular diagnostic products and molecular genetic diagnostic products. The cancer molecular diagnostic segment includes specific tests for colorectal cancer, bladder cancer, lung cancer, stomach cancer, and cervical cancer. This targeted approach allows the firm to address a broad spectrum of oncological needs within the diagnostic market. Within the molecular genetic diagnostic products category, Genomictree, Inc. provides epidermal growth factor receptor (EGFR) mutation diagnosis and human papilloma virus (HPV) diagnostic products. By offering these specialized genetic tests, the company serves the healthcare sector with tools necessary for precise patient diagnosis and treatment planning based on genomic data. Genomictree is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genomictree stock

Operating Cash Flow Margin of Genomictree is -271.08 % in 2025.

Operating Cash Flow Margin of Genomictree changed from -577.12 % to -271.08 %, representing a -53.03% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Genomictree since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Genomictree with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Genomictree

All Key Metrics — Genomictree